http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021053955-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_872dd7cd609eb2a937dcfd303d521798 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-048 |
| filingDate | 2019-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c605793dba2437bdce090051f6b4c02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4466c1965a5845c70d57cce08034f8ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2689457b29f10d56fcff5b26d3a8aeb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7ca939c33d3d924eefa113ff5ac9a5f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5055d822a29afdf7d54a241010492e2 |
| publicationDate | 2021-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2021053955-A1 |
| titleOfInvention | Ghrelin o-acyltransferase inhibitors |
| abstract | This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g., alcohol, smoking, overeating, or use of illicit drugs))), as well as disorders related to or complications of metabolic or psychiatric disorders (e.g., cardiovascular diseases (e.g., diabetic heart disease (e.g., diabetic cardiomyopathy), heart failure, or hypertension), ischemia (e.g., myocardial ischemia, cerebral ischemia, ischemic stroke), or BMI-related cancers (e.g., pancreatic cancer, gallbladder cancer, esophageal cancer, colorectal cancer, breast cancer etc.). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023122754-A1 |
| priorityDate | 2018-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1396.